Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer - report from ESMO2023

Professor Krishnansu Sujata Tewari explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. These are the late-breaking results presented at ESMO 2023 congress. Video: https://medicaldigest.org/scientific-contents/interview:antibody-drug-conjugate-boosts-survival-recurrentmetastatic-cervical-cancer